EC approves Santhera's Raxone for LHON

Santhera Pharmaceuticals Holding AG (SIX:SANN) said the European Commission approved an MAA for Raxone idebenone to treat visual impairment in adolescent and adult patients with Leber's hereditary optic neuropathy (LHON). Santhera said the drug will be available immediately in some countries. Santhera gained CHF5.20 to CHF99 on Wednesday.

In June, EMA's CHMP recommended approval of the short-chain benzoquinone under the agency's exceptional circumstances clause (see BioCentury Extra, June 26). ...